{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:44:55Z","timestamp":1790361895289,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14758-w","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T06:47:45Z","timestamp":1756709265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular mechanisms of astragaloside-IV in hepatocellular carcinoma therapy: a systematic review"],"prefix":"10.1186","volume":"25","author":[{"given":"Xin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaqiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiye","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"6","key":"14758_CR1","first-page":"865","volume":"45","author":"WG Miao","year":"2024","unstructured":"Miao WG, Zhou JY, Han RQ. Analysis of global liver cancer statistics. Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi. 2024;45(6):865\u20139.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi"},{"issue":"3","key":"14758_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"14758_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42(2):180\u201397.","journal-title":"Cancer Cell"},{"key":"14758_CR4","doi-asserted-by":"publisher","unstructured":"Chan YT, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Molr cancer. 2024;23(1):189. https:\/\/doi.org\/10.1186\/s12943-024-02101-z.","DOI":"10.1186\/s12943-024-02101-z"},{"issue":"6","key":"14758_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","volume":"81","author":"C Fuster-Anglada","year":"2024","unstructured":"Fuster-Anglada C, et al. Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol. 2024;81(6):995\u20131004.","journal-title":"J Hepatol"},{"key":"14758_CR6","doi-asserted-by":"publisher","unstructured":"Buyel JF. Plants as sources of natural and recombinant anti-cancer agents. Biotechnol Adv. 2018;36(2):506\u2013520. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.02.002.","DOI":"10.1016\/j.biotechadv.2018.02.002"},{"key":"14758_CR7","doi-asserted-by":"publisher","unstructured":"Gao Q, et al. Natural lipid nanoparticles extracted from Morus nigra L. leaves for targeted treatment of hepatocellular carcinoma via the oral route. J Nanobiotechnol.2024;22(1):4. https:\/\/doi.org\/10.1186\/s12951-023-02286-3.","DOI":"10.1186\/s12951-023-02286-3"},{"issue":"6","key":"14758_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.it.2020.04.004","volume":"41","author":"SY van der Zanden","year":"2020","unstructured":"van der Zanden SY, Luimstra JJ, Neefjes J, Borst J, Ovaa H. Opportunities for small molecules in cancer immunotherapy. Trends Immunol. 2020;41(6):493\u2013511.","journal-title":"Trends Immunol"},{"key":"14758_CR9","doi-asserted-by":"publisher","unstructured":"Xi Z, et al. Traditional Chinese medicine in lung cancer treatment. Molecular cancer. 2025;24(1):57. https:\/\/doi.org\/10.1186\/s12943-025-02245-6.","DOI":"10.1186\/s12943-025-02245-6"},{"key":"14758_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100881","volume":"65","author":"ER Smith","year":"2022","unstructured":"Smith ER, Wang JQ, Yang DH, Xu XX. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat. 2022;65: 100881.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"14758_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","volume":"5","author":"YX Chen","year":"2020","unstructured":"Chen YX, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267\u201375.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"14758_CR12","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1142\/S0192415X20500780","volume":"48","author":"S Wang","year":"2020","unstructured":"Wang S, Long S, Deng Z, Wu W. Positive role of Chinese herbal medicine in cancer immune regulation. Am J Chin Med. 2020;48(7):1577\u201392.","journal-title":"Am J Chin Med"},{"key":"14758_CR13","doi-asserted-by":"publisher","unstructured":"Kitagawa I, et al. Saponin and Sapogenol. XXXIV. Chemical Constituents of Astragali Radix, the Root of Astragalus membranaceus BUNGE. (1). Cycloastragenol, the 9, 19-Cycloanostane-type Aglycone of Astragalosides, and the Artifact Aglycone Astragenol. Chem Pharm Bull. 1983;31(2):689\u2013697. https:\/\/doi.org\/10.1248\/cpb.31.689.","DOI":"10.1248\/cpb.31.689"},{"issue":"6","key":"14758_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1142\/S0192415X1750063X","volume":"45","author":"Y Qi","year":"2017","unstructured":"Qi Y, Gao F, Hou L, Wan C. Anti-inflammatory and immunostimulatory activities of astragalosides. Am J Chin Med. 2017;45(6):1157\u201367.","journal-title":"Am J Chin Med"},{"key":"14758_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2021.4846","author":"T Chen","year":"2021","unstructured":"Chen T, Yang P, Jia Y. Molecular mechanisms of astragaloside-IV in cancer therapy (review). Int J Mol Med. 2021. https:\/\/doi.org\/10.3892\/ijmm.2021.4846.","journal-title":"Int J Mol Med"},{"key":"14758_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1065505","volume":"14","author":"D Xia","year":"2023","unstructured":"Xia D, Li W, Tang C, Jiang J. Astragaloside IV, as a potential anticancer agent. Front Pharmacol. 2023;14: 1065505.","journal-title":"Front Pharmacol"},{"key":"14758_CR17","doi-asserted-by":"publisher","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed).2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"14758_CR18","doi-asserted-by":"publisher","unstructured":"Cumpston M, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane database of systematic reviews.2019;10(10):Ed000142. https:\/\/doi.org\/10.1002\/14651858.Ed000142.","DOI":"10.1002\/14651858.Ed000142"},{"key":"14758_CR19","doi-asserted-by":"publisher","unstructured":"Ma PF, Ruan B, Wang DS, Dou KF. Study on the Effect and Mechanism of Astragaloside A on the Proliferation and Invasion Ability of Hepatoma Cells. 2014;(5):1012\u20131015. https:\/\/doi.org\/10.3969\/j.issn.1672-4992.2014.05.10.","DOI":"10.3969\/j.issn.1672-4992.2014.05.10"},{"key":"14758_CR20","doi-asserted-by":"publisher","unstructured":"An XC, Zhu RX, Lin SM, Shi L. The mechanism by which astragaloside A inhibits the ROS NF-\u03baB signaling pathway and promotes the proliferation and apoptosis of hepatoma cells. 2019;24(12):1399\u20131403. https:\/\/doi.org\/10.3969\/j.issn.1672-2159.2019.12.008.","DOI":"10.3969\/j.issn.1672-2159.2019.12.008"},{"key":"14758_CR21","doi-asserted-by":"publisher","unstructured":"Li L, et al. Astragaloside IV suppresses migration and invasion of TGF-\u03b2(1)-induced human hepatoma HuH-7 cells by regulating Nrf2\/HO-1 and TGF-\u03b2(1)\/Smad3 pathways. Naunyn Schmiedebergs Arch Pharmacol.2022 3;395(4):397\u2013405. https:\/\/doi.org\/10.1007\/s00210-021-02199-8.","DOI":"10.1007\/s00210-021-02199-8"},{"key":"14758_CR22","doi-asserted-by":"publisher","unstructured":"Li Y, Ye Y, Chen H. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB. Biomed Pharmacother = Biomed Pharmacother. 2018;99:134\u2013141. https:\/\/doi.org\/10.1016\/j.biopha.2017.12.108.","DOI":"10.1016\/j.biopha.2017.12.108"},{"key":"14758_CR23","doi-asserted-by":"publisher","unstructured":"Wang PP, et al. Astragaloside IV downregulates the expression of MDR1 in Bel\u20117402\/FU human hepatic cancer cells by inhibiting the JNK\/c\u2011Jun\/AP\u20111 signaling pathway. Mol Med Rep. 2017;16(3):2761\u20132766. https:\/\/doi.org\/10.3892\/mmr.2017.6924.","DOI":"10.3892\/mmr.2017.6924"},{"key":"14758_CR24","doi-asserted-by":"publisher","unstructured":"Su CM, et al. Astragaloside IV Induces Apoptosis, G(1)-Phase Arrest and Inhibits Anti-apoptotic Signaling in Hepatocellular Carcinoma. In vivo (Athens, Greece). 2020 6;34(2):631\u2013638. https:\/\/doi.org\/10.21873\/invivo.11817.","DOI":"10.21873\/invivo.11817"},{"key":"14758_CR25","doi-asserted-by":"publisher","unstructured":"He T, Wang FF, Liu ZQ, He QH. Astragaloside A affects the proliferation and apoptosis of HepG-2 cells through the Wnt\/\u03b2-catenin pathway. 2020;15(24):3787\u20133791. https:\/\/doi.org\/10.3969\/j.issn.1673-7202.2020.24.011.","DOI":"10.3969\/j.issn.1673-7202.2020.24.011"},{"issue":"3","key":"14758_CR26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3892\/or.2017.5389","volume":"37","author":"CD Qin","year":"2017","unstructured":"Qin CD, et al. Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt\/GSK-3\u03b2\/\u03b2-catenin pathway. Oncol Rep. 2017;37(3):1725\u201335.","journal-title":"Oncol Rep"},{"key":"14758_CR27","doi-asserted-by":"publisher","unstructured":"Zhang S, et al. Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma. Anticancer Res. 2017;37(2):465\u2013473. https:\/\/doi.org\/10.21873\/anticanres.11338.","DOI":"10.21873\/anticanres.11338"},{"key":"14758_CR28","doi-asserted-by":"publisher","unstructured":"Cui X, Jiang X, Wei C, Xing Y, Tong G. Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150\u20135p\/\u03b2-catenin axis. Environment Toxicol Pharmacol. 2020 8;78:103397. https:\/\/doi.org\/10.1016\/j.etap.2020.103397.","DOI":"10.1016\/j.etap.2020.103397"},{"key":"14758_CR29","doi-asserted-by":"publisher","unstructured":"Zhu Y, Lu F. Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1. BMC Cancer. 2024;24(1):682. https:\/\/doi.org\/10.1186\/s12885-024-12438-9.","DOI":"10.1186\/s12885-024-12438-9"},{"key":"14758_CR30","doi-asserted-by":"publisher","unstructured":"Ma Y, Li Y, Wu T, Li Y, Wang Q. Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p\/CNDP1 Axis. Cancers. 2023;15(20)https:\/\/doi.org\/10.3390\/cancers15205048.","DOI":"10.3390\/cancers15205048"},{"key":"14758_CR31","doi-asserted-by":"publisher","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129. https:\/\/doi.org\/10.1186\/s13045-022-01347-8.","DOI":"10.1186\/s13045-022-01347-8"},{"key":"14758_CR32","doi-asserted-by":"publisher","unstructured":"Fang Gong Y, et al. Amelioratory effects of astragaloside IV on hepatocarcinogenesis via Nrf2-mediated pSmad3C\/3L transformation. Phytomedicine. 2023;117:154903. https:\/\/doi.org\/10.1016\/j.phymed.2023.154903.","DOI":"10.1016\/j.phymed.2023.154903"},{"key":"14758_CR33","doi-asserted-by":"publisher","unstructured":"Qu X, et al. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2. Eur J Pharmaceut Sci. 2020;148:105325. https:\/\/doi.org\/10.1016\/j.ejps.2020.105325.","DOI":"10.1016\/j.ejps.2020.105325"},{"key":"14758_CR34","unstructured":"Min L, Wang H, Qi H. Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4\/NF-\u03baB\/STAT3 signaling pathway. Am J Transl Res. 2022 14;14(3):1551\u20131566."},{"issue":"1","key":"14758_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","volume":"20","author":"A Moyer","year":"2025","unstructured":"Moyer A, Tanaka K, Cheng EH. Apoptosis in cancer biology and therapy. Annu Rev Pathol Mech Dis. 2025;20(1):303\u201328.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"14758_CR36","doi-asserted-by":"publisher","unstructured":"Hooijmans CR, et al. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodology.2014;14:43. https:\/\/doi.org\/10.1186\/1471-2288-14-43.","DOI":"10.1186\/1471-2288-14-43"},{"key":"14758_CR37","doi-asserted-by":"publisher","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncology. 2021;14(1):10. https:\/\/doi.org\/10.1186\/s13045-020-01027-5.","DOI":"10.1186\/s13045-020-01027-5"},{"key":"14758_CR38","doi-asserted-by":"publisher","unstructured":"Wang C, et al. Role of succinylation modification in central nervous system diseases. Ageing Res Rev. Mar 2024;95:102242. https:\/\/doi.org\/10.1016\/j.arr.2024.102242.","DOI":"10.1016\/j.arr.2024.102242"},{"key":"14758_CR39","doi-asserted-by":"publisher","unstructured":"Zhang C, et al. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C\/3L and Nrf2\/HO-1 pathways. J Ethnopharmacol. 2021\/10\/28\/ 2021 11;279:114350. https:\/\/doi.org\/10.1016\/j.jep.2021.114350.","DOI":"10.1016\/j.jep.2021.114350"},{"key":"14758_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59: 100796.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"14758_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","volume":"7","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11\u201320.","journal-title":"Cell Metab"},{"key":"14758_CR42","doi-asserted-by":"publisher","unstructured":"Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417\u201327. https:\/\/doi.org\/10.1038\/nrd3455.","DOI":"10.1038\/nrd3455"},{"key":"14758_CR43","unstructured":"Rooney AJNTPOoHA, Translation. Extending a risk-of-bias approach to address in vitro studies. 2015."},{"key":"14758_CR44","doi-asserted-by":"publisher","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864\u2013884. https:\/\/doi.org\/10.1038\/s41571-023-00825-3.","DOI":"10.1038\/s41571-023-00825-3"},{"key":"14758_CR45","doi-asserted-by":"publisher","unstructured":"Shi X, et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct Target Therapy. 2024;9(1):192. https:\/\/doi.org\/10.1038\/s41392-024-01885-2.","DOI":"10.1038\/s41392-024-01885-2"},{"issue":"5","key":"14758_CR46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12094-017-1774-3","volume":"20","author":"C Yang","year":"2018","unstructured":"Yang C, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 2018;20(5):570\u20135.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"14758_CR47","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tips.2014.02.004","volume":"35","author":"SC Wang","year":"2014","unstructured":"Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35(4):178\u201386.","journal-title":"Trends Pharmacol Sci"},{"key":"14758_CR48","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.biopha.2018.03.127","volume":"102","author":"S Wang","year":"2018","unstructured":"Wang S, Mou J, Cui L, Wang X, Zhang Z. Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7\u2013H3. Biomed Pharmacother. 2018;102:1037\u201344.","journal-title":"Biomed Pharmacother"},{"key":"14758_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.intimp.2016.10.001","volume":"42","author":"K Jiang","year":"2017","unstructured":"Jiang K, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1\/MAPK signaling. Int Immunopharmacol. 2017;42:195\u2013202.","journal-title":"Int Immunopharmacol"},{"key":"14758_CR50","doi-asserted-by":"publisher","unstructured":"Qiu T, et al. Astragaloside IV Inhibits the Proliferation of Human Uterine Leiomyomas by Targeting IDO1. Cancers. 2022;14(18)https:\/\/doi.org\/10.3390\/cancers14184424.","DOI":"10.3390\/cancers14184424"},{"key":"14758_CR51","doi-asserted-by":"publisher","unstructured":"Ma Q, Lu X, Tian W, Chen Y, He X. Astragaloside IV mediates the effect and mechanism of KPNB1 on biological behavior and tumor growth in prostate cancer. Heliyon. 2024;10(13):e33904. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33904.","DOI":"10.1016\/j.heliyon.2024.e33904"},{"key":"14758_CR52","doi-asserted-by":"publisher","unstructured":"Zhao Y, et al. Astragaloside IV inhibits cell proliferation in vulvar squamous cell carcinoma through the TGF-\u03b2\/Smad signaling pathway. Dermatol Therapy. 2019;32(4):e12802. https:\/\/doi.org\/10.1111\/dth.12802.","DOI":"10.1111\/dth.12802"},{"key":"14758_CR53","doi-asserted-by":"publisher","unstructured":"Tan Y, et al. Tumor-derived exosomal components: the multifaceted roles and mechanisms in breast cancer metastasis. Cell Death Dis. 2021;12(6):547. https:\/\/doi.org\/10.1038\/s41419-021-03825-2.","DOI":"10.1038\/s41419-021-03825-2"},{"key":"14758_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111450","volume":"138","author":"S Xie","year":"2021","unstructured":"Xie S, Wu Z, Qi Y, Wu B, Zhu X. The metastasizing mechanisms of lung cancer: recent advances and therapeutic challenges. Biomed Pharmacother. 2021;138: 111450.","journal-title":"Biomed Pharmacother"},{"key":"14758_CR55","doi-asserted-by":"publisher","unstructured":"Liu W, Chen H, Wang D. Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195\u20135p-mediated PD-L1. Immunopharmacol Immunotoxicol. 2021;43(4):443\u2013451. https:\/\/doi.org\/10.1080\/08923973.2021.1936013.","DOI":"10.1080\/08923973.2021.1936013"},{"key":"14758_CR56","doi-asserted-by":"publisher","unstructured":"Shen L, et al. Astragaloside IV suppresses the migration and EMT progression of cervical cancer cells by inhibiting macrophage M2 polarization through TGF\u03b2\/Smad2\/3 signaling. Function Integrat Genomics. 2023;23(2):133. https:\/\/doi.org\/10.1007\/s10142-023-01017-z.","DOI":"10.1007\/s10142-023-01017-z"},{"key":"14758_CR57","doi-asserted-by":"publisher","unstructured":"Yin W, Liao X, Sun J, Chen Q, Fan S. Astragaloside IV inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of oral cancer cells by aggravating autophagy. Tissue Cell. Oct 2024;90:102524. https:\/\/doi.org\/10.1016\/j.tice.2024.102524.","DOI":"10.1016\/j.tice.2024.102524"},{"key":"14758_CR58","doi-asserted-by":"publisher","unstructured":"Zhu J, Wen K. Astragaloside IV inhibits TGF-\u03b21-induced epithelial-mesenchymal transition through inhibition of the PI3K\/Akt\/NF-\u03baB pathway in gastric cancer cells. Phytother Res. 2018;32(7):1289\u20131296. https:\/\/doi.org\/10.1002\/ptr.6057.","DOI":"10.1002\/ptr.6057"},{"issue":"3","key":"14758_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5603\/GP.a2021.0113","volume":"93","author":"YY Zhao","year":"2022","unstructured":"Zhao YY, Zhang HY. Astragaloside IV inhibits cell invasion and metastasis in vulvar squamous cell carcinoma through the TGF-\u03b21\/FAK\/AKT signaling pathway. Ginekol Pol. 2022;93(3):179\u201384.","journal-title":"Ginekol Pol"},{"key":"14758_CR60","doi-asserted-by":"publisher","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395\u2013417. https:\/\/doi.org\/10.1038\/s41571-020-0341-y.","DOI":"10.1038\/s41571-020-0341-y"},{"key":"14758_CR61","doi-asserted-by":"publisher","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175\u2013193. https:\/\/doi.org\/10.1038\/s41580-018-0089-8.","DOI":"10.1038\/s41580-018-0089-8"},{"key":"14758_CR62","doi-asserted-by":"publisher","unstructured":"Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2(4):277\u201388. https:\/\/doi.org\/10.1038\/nrc776.","DOI":"10.1038\/nrc776"},{"key":"14758_CR63","doi-asserted-by":"publisher","unstructured":"Kong P, Tang X, Liu F, Tang X. Astragaloside IV regulates circ_0001615 and miR-873\u20135p\/LASP1 axis to suppress colorectal cancer cell progression. Chem Biol Drug Design. 2024;103(1):e14423. https:\/\/doi.org\/10.1111\/cbdd.14423.","DOI":"10.1111\/cbdd.14423"},{"key":"14758_CR64","doi-asserted-by":"publisher","unstructured":"Wu T, et al. Astragaloside IV augments anti-PD-1 therapy to suppress tumor growth in lung cancer by remodeling the tumor microenvironment. Eur J Histochem. 2024;68(4)https:\/\/doi.org\/10.4081\/ejh.2024.4098.","DOI":"10.4081\/ejh.2024.4098"},{"issue":"4","key":"14758_CR65","first-page":"503","volume":"27","author":"L Jia","year":"2019","unstructured":"Jia L, Lv D, Zhang S, Wang Z, Zhou B. Astragaloside IV inhibits the progression of non-small cell lung cancer through the Akt\/GSK-3\u03b2\/\u03b2-catenin pathway. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2019;27(4):503\u20138.","journal-title":"Oncol Res Featur Preclin Clin Cancer Therap"},{"key":"14758_CR66","doi-asserted-by":"publisher","unstructured":"Tong X, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15(1):174. https:\/\/doi.org\/10.1186\/s13045-022-01392-3.","DOI":"10.1186\/s13045-022-01392-3"},{"key":"14758_CR67","doi-asserted-by":"publisher","unstructured":"Hu T, Fei Z, Wei N. Chemosensitive effects of Astragaloside IV in osteosarcoma cells via induction of apoptosis and regulation of caspase-dependent Fas\/FasL signaling. Pharm Rep. 2017;69(6):1159\u20131164. https:\/\/doi.org\/10.1016\/j.pharep.2017.07.001.","DOI":"10.1016\/j.pharep.2017.07.001"},{"issue":"9","key":"14758_CR68","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20(9):604\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"14758_CR69","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","volume":"186","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Schwab RD, Brookens SK, Posey AD Jr. Advances in cancer immunotherapies. Cell. 2023;186(8):1814-1814.e1. https:\/\/doi.org\/10.1016\/j.cell.2023.02.039.","journal-title":"Cell"},{"key":"14758_CR70","doi-asserted-by":"publisher","unstructured":"Yi M, et al. Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023;22(1):187. https:\/\/doi.org\/10.1186\/s12943-023-01885-w.","DOI":"10.1186\/s12943-023-01885-w"},{"issue":"11","key":"14758_CR71","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00432-014-1744-x","volume":"140","author":"A Zhang","year":"2014","unstructured":"Zhang A, et al. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. J Cancer Res Clin Oncol. 2014;140(11):1883\u201390.","journal-title":"J Cancer Res Clin Oncol"},{"key":"14758_CR72","doi-asserted-by":"publisher","unstructured":"Liu F, Ran F, He H, Chen L. Astragaloside IV Exerts Anti-tumor Effect on Murine Colorectal Cancer by Re-educating Tumor-Associated Macrophage. Arch Immunol Ther Exper. Oct 23 2020;68(6):33. https:\/\/doi.org\/10.1007\/s00005-020-00598-y.","DOI":"10.1007\/s00005-020-00598-y"},{"key":"14758_CR73","doi-asserted-by":"publisher","unstructured":"Gao H, et al. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options. Mol Cancer. May 3 2024;23(1):88. https:\/\/doi.org\/10.1186\/s12943-024-02005-y.","DOI":"10.1186\/s12943-024-02005-y"},{"key":"14758_CR74","doi-asserted-by":"publisher","unstructured":"Zheng Y, et al. Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage. J Cell Physiol. 2019;234(4):4277\u20134290. https:\/\/doi.org\/10.1002\/jcp.27196.","DOI":"10.1002\/jcp.27196"},{"key":"14758_CR75","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jep.2018.09.026","volume":"228","author":"Y Lou","year":"2019","unstructured":"Lou Y, et al. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein. J Ethnopharmacol. 2019;228:82\u201391.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"14758_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317697555","volume":"39","author":"PC Dai","year":"2017","unstructured":"Dai PC, et al. Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6. Tumor Biol. 2017;39(4): 1010428317697555.","journal-title":"Tumor Biol"},{"key":"14758_CR77","doi-asserted-by":"publisher","unstructured":"Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discove. 2023;22(6):476\u2013495. https:\/\/doi.org\/10.1038\/s41573-023-00671-z.","DOI":"10.1038\/s41573-023-00671-z"},{"issue":"11","key":"14758_CR78","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","volume":"24","author":"L P\u00e9rez-Guti\u00e9rrez","year":"2023","unstructured":"P\u00e9rez-Guti\u00e9rrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023;24(11):816\u201334.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"14758_CR79","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, et al. Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30\u20139.","journal-title":"Clin Cancer Res"},{"key":"14758_CR80","doi-asserted-by":"publisher","unstructured":"Lim JS, et al. Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth. Cell Death Dis. 2022;13(11):1002. https:\/\/doi.org\/10.1038\/s41419-022-05449-6.","DOI":"10.1038\/s41419-022-05449-6"},{"key":"14758_CR81","doi-asserted-by":"publisher","unstructured":"Li B, Wang F, Liu N, Shen W, Huang T. Astragaloside IV inhibits progression of glioma via blocking MAPK\/ERK signaling pathway. Biochem Biophys Res Commun. 2017;491(1):98\u2013103. https:\/\/doi.org\/10.1016\/j.bbrc.2017.07.052.","DOI":"10.1016\/j.bbrc.2017.07.052"},{"key":"14758_CR82","doi-asserted-by":"publisher","unstructured":"Rizzo G, Bertotti A, Leto SM, Vetrano S. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. J Exp Clin Cancer Res. 2021;40(1):178. https:\/\/doi.org\/10.1186\/s13046-021-01970-2.","DOI":"10.1186\/s13046-021-01970-2"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14758-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14758-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14758-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:58:17Z","timestamp":1757465897000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14758-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14758"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14758-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1407"}}